scholarly journals Guillain-Barre Syndrome after Kidney Transplantation: a Case Report

2013 ◽  
Vol 2 (1) ◽  
pp. 35-36
Author(s):  
Mohsen Farazdaghi ◽  
Anahita Zoghi ◽  
Afshin Borhani Haghighi
Keyword(s):  
Kidney Transplantation ◽  
Organ Transplantation ◽  
Solid Organ Transplantation ◽  
Guillain Barre Syndrome ◽  
Unusual Complication ◽  
Solid Organ ◽  
Hematopoietic Stem ◽  
Guillain Barré Syndrome ◽  
Associated Symptoms ◽  
Guillain Barré

Background: Guillain-Barre Syndrome is an unusual complication of hematopoietic stem cell transplantation but it is extremely rare after solid organ transplantation such as kidney or liver transplantationCase report: A 48-year-old man, a case of kidney transplantation presented with generalized weakness in an ascending pattern. History and examination were compatible with the diagnosis of Guillain-Barre Syndrome (GBS) and paraclinical studies confirmed this diagnosis. He was treated for Guillain-Barre syndrome but no significant response was observed.Conclusion: Guillain–Barre´ syndrome rarely appears after organ transplantation but it should be considered in a patient presenting with its associated symptoms after transplantation.

GUILLAIN-BARRE SYNDROME AFTER SOLID ORGAN TRANSPLANTATION

2001 ◽  
Vol 71 (9) ◽  
pp. 1311-1316 ◽  
Author(s):  
Rafik A. El-Sabrout ◽  
Branislav Radovancevic ◽  
Victor Ankoma-Sey ◽  
and Charles T. Van Buren
Keyword(s):  
Organ Transplantation ◽  
Solid Organ Transplantation ◽  
Guillain Barre Syndrome ◽  
Solid Organ ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Treatment of Kaposi's sarcoma after solid organ transplantation.

1997 ◽  
Vol 15 (6) ◽  
pp. 2371-2377 ◽  
Author(s):  
F A Shepherd ◽  
E Maher ◽  
C Cardella ◽  
E Cole ◽  
P Greig ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Organ Transplantation ◽  
Combination Chemotherapy ◽  
Kaposi's Sarcoma ◽  
Solid Organ Transplantation ◽  
Kaposi’S Sarcoma ◽  
Skin Toxicity ◽  
Solid Organ ◽  
Duration Of Response ◽  
Italian Origin

PURPOSE This retrospective review of all patients who developed Kaposi's sarcoma (KS) after solid organ transplantation at a single institution was undertaken to define the clinical presentation of this malignancy in the setting of iatrogenic immunodeficiency, and to determine the most appropriate treatment for patients in this clinical setting. MATERIALS AND METHODS The records of 2,099 patients who underwent heart, lung, liver, or kidney transplantation at The Toronto Hospital between January 1, 1981 and June 30, 1995, were reviewed. Twelve patients were identified who developed biopsy-proven KS in the posttransplantation period. Five patients who had disseminated KS who had not responded to either reduction or withdrawal of immunosuppression or to local radiotherapy were treated with combination chemotherapy consisting of doxorubicin 20 to 30 mg/m2, bleomycin 10 mg/m2, and vincristine 2 mg (ABV) administered intravenously every 3 weeks. RESULTS Eight of 12 patients were male and nine were of Italian origin. KS was limited to a localized area of the skin for only six patients, all after kidney transplantation. Visceral KS was present in three patients. Four of five patients responded to ABV chemotherapy (two complete and two partial remissions). The fifth patient responded to second-line etoposide and cisplatin. The median duration of response was in excess of 13 months (range, 8+ to 45+ months). Toxicity was limited to grade 1 neurotoxicity and grade 1 skin toxicity. CONCLUSION KS is an uncommon but recognized complication of solid organ transplantation. Combination chemotherapy is a safe and effective treatment for patients with disseminated or visceral KS that fails to respond to changes in immunosuppression.

Sign in / Sign up

Export Citation Format

Share Document